Duality Advisers’s Editas Medicine EDIT Stock Holding History

Duality Advisers’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22,546	Closed	-$599K	–	680
2021 Q4	$599K	Sell	22,546 -19,974	-47%	-$687K	0.06%	384
2021 Q3	$1.75M	Buy	+42,520	New	+$2.33M	0.13%	267
2020 Q4	–	Sell	-24,460	Closed	-$686K	–	597
2020 Q3	$686K	Buy	+24,460	New	+$797K	0.04%	434

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Duality Advisers's EDIT Position: Q1 2022 in Review

Duality Advisers sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 22,546 shares — an estimated $599K sold.

Duality Advisers first reported a position in EDIT in Q3 2020 and held it in 3 quarters. The position peaked at $1.75M in Q3 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

Duality Advisers reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
Duality Advisers sold 22,546 Editas Medicine shares in Q1 2022, an estimated $599K.
Duality Advisers first reported a position in Editas Medicine in Q3 2020 and held it in 3 quarters.
Duality Advisers's Editas Medicine position peaked at $1.75M in Q3 2021.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Duality Advisers's 13F filing for Q1 2022, filed 9 May 2022.